Oncolytic virus platform to treat hematological cancer

Patent metadata

Field	Value
Publication number	US-12569526-B2
Application number	US-201917274051-A
Country	US
Kind code	B2
Filing date	Sep 4, 2019
Priority date	Sep 5, 2018
Publication date	Mar 10, 2026
Grant date	Mar 10, 2026

Abstract

The disclosure provides Myxoma virus that expresses one or more immunomodulatory transgenes and its use in inhibiting and/or treating a hematological cancer in a subject. The disclosure also provides a leukocyte having a Myxoma virus that expresses one or more immunomodulatory transgenes and the use of the leukocyte for inhibiting and/or treating a hematological cancer in a subject.

First claim

We claim:

1 . A myxoma virus (MXYV) comprising one or more immunomodulatory transgenes, wherein the one or more immunomodulatory transgenes encode a BiKE (Bi-specific Natural Killer and Neutrophil engager), wherein the BiKE comprises a first single chain variable fragment (scFv) that binds to CD16 and a second scFv that binds to a cancer-specific cell surface marker, wherein the cancer-specific cell surface marker is CD138, wherein the BiKE comprises SEQ ID NO:6.

2 . The MYXV of claim 1 , wherein the immunomodulatory transgene is inserted in the MYXV genome within or adjacent to a gene that modulates MYXV replication in a cancer cell, a gene that is associated with an ability of the MYXV to cause disease in a host animal, a gene that is associated with host cell tropism, a gene that is associated with an ability of the MYXV to evade an innate immune response, a gene that modulates immune signaling in an infected cell, or a gene that modulates a cell death pathway in an infected cell.

3 . The MYXV of claim 1 , wherein the one or more immunomodulatory transgenes further comprise a LIGHT (Lymphotoxins-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus entry mediator (HVEM), a receptor expressed by T lymphocytes).

4 . The MYXV of claim 3 , wherein the LIGHT comprises SEQ ID NO: 13.

5 . The MYXV of claim 1 , wherein the one or more immunomodulatory transgenes further comprise a decorin.

6 . The MYXV of claim 5 , wherein the decorin comprises SEQ ID NO: 7.

7 . The MYXV of claim 1 , wherein the immunomodulatory transgene is inserted between M135 and M136 open reading frames of the MYXV genome.

8 . The MYXV of claim 1 , wherein the MYXV comprises a gene deletion or disruption in its genome.

9 . The MYXV of claim 8 , wherein the gene deletion or disruption is present in one or more genes selected from the group consisting of M001R, M002R, M003.1R, M003.2R, M004.1R, M004R, M005R, M006R, M007R, M008.1R, M008R, M009L, M013, M036L, M063L, M11L, M128L, M131R, M135R, M136R, M141R, M148R, M151R, M152R, M153R, M154L, M156R, M-T2, M-T4, M-T5, M-T7, and SOD.

10 . The MYXV of claim 1 , wherein the MYXV is a genetically modified Laussane strain MYXV.

11 . The MYXV of claim 1 , wherein the MYXV is capable of infecting and killing cancer cells from a subject with drug-refractory cancer.

12 . The MYXV of claim 1 , wherein the MYXV is capable of directly killing cancer cells infected by the MYXV and eliciting off-target killing of uninfected cancer cells.

Assignees

• Univ Arizona State

Inventors

• Mcfadden Douglas Grant
• Torres-Dominguez Lino
• Villa Nancy
• Rahman Mohammed Masmudur

Classifications

• A61K40/50

  characterised by the use of allogeneic cells · CPC title

• A61K40/42

  Cancer antigens · CPC title

• A61K40/10

  characterised by the cell type used · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title

• C12N2710/24032

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title